scholarly journals Effect of Peroxisome Proliferator-Activated Receptor   Agonist Treatment on Subclinical Atherosclerosis in Patients With Insulin-Requiring Type 2 Diabetes

Diabetes Care ◽  
2006 ◽  
Vol 29 (7) ◽  
pp. 1545-1553 ◽  
Author(s):  
H. N. Hodis ◽  
W. J. Mack ◽  
L. Zheng ◽  
Y. Li ◽  
M. Torres ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Subclinical Atherosclerosis ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

scholarly journals Effect of a Peroxisome Proliferator-Activated Receptor-  Agonist on Myocardial Blood Flow in Type 2 Diabetes

Diabetes Care ◽  
2005 ◽  
Vol 28 (5) ◽  
pp. 1145-1150 ◽  
Author(s):  
G. T. McMahon ◽  
J. Plutzky ◽  
E. Daher ◽  
T. Bhattacharyya ◽  
G. Grunberger ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Flow ◽  
Myocardial Blood Flow ◽  
Receptor Agonist ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

Bezafibrate, a peroxisome proliferator–activated receptor α agonist, decreases circulating CD14+CD16+ monocytes in patients with type 2 diabetes

2015 ◽  
Vol 165 (2) ◽  
pp. 336-345 ◽  
Author(s):  
Tomoko Terasawa ◽  
Yoshimasa Aso ◽  
Kyoko Omori ◽  
Maiko Fukushima ◽  
Atsushi Momobayashi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

scholarly journals Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism

2006 ◽  
Vol 92 (2) ◽  
pp. 386-395 ◽  
Author(s):  
Arya M. Sharma ◽  
Bart Staels
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Fatty Acid ◽  
Endocrine Function ◽  
Low Grade ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

Abstract Context: Adipose tissue is a metabolically dynamic organ, serving as a buffer to control fatty acid flux and a regulator of endocrine function. In obese subjects, and those with type 2 diabetes or the metabolic syndrome, adipose tissue function is altered (i.e. adipocytes display morphological differences alongside aberrant endocrine and metabolic function and low-grade inflammation). Evidence Acquisition: Articles on the role of peroxisome proliferator-activated receptor γ (PPARγ) in adipose tissue of healthy individuals and those with obesity, metabolic syndrome, or type 2 diabetes were sourced using MEDLINE (1990–2006). Evidence Synthesis: Articles were assessed to provide a comprehensive overview of how PPARγ-activating ligands improve adipose tissue function, and how this links to improvements in insulin resistance and the progression to type 2 diabetes and atherosclerosis. Conclusions: PPARγ is highly expressed in adipose tissue, where its activation with thiazolidinediones alters fat topography and adipocyte phenotype and up-regulates genes involved in fatty acid metabolism and triglyceride storage. Furthermore, PPARγ activation is associated with potentially beneficial effects on the expression and secretion of a range of factors, including adiponectin, resistin, IL-6, TNFα, plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, and angiotensinogen, as well as a reduction in plasma nonesterified fatty acid supply. The effects of PPARγ also extend to macrophages, where they suppress production of inflammatory mediators. As such, PPARγ activation appears to have a beneficial effect on the relationship between the macrophage and adipocyte that is distorted in obesity. Thus, PPARγ-activating ligands improve adipose tissue function and may have a role in preventing progression of insulin resistance to diabetes and endothelial dysfunction to atherosclerosis.

Sign in / Sign up

Export Citation Format

Share Document